Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
Emergent BioSolutions reported third quarter 2026 results on November 2, 2026, alongside several operating updates. The company said it is based in Gaithersburg, Maryland1 and issued a press release on November 2, 2026 announcing results for the quarter ended September 30, 20261.
On contracts, Emergent reported it was awarded a contract modification valued at approximately $24 million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)1 and awarded a 'Standing Offer' for NARCAN® Nasal Spray from the Government of Canada1.
Emergent lowered its full-year 2026 financial forecast. The company now expects total revenues of $600 to $645 million, versus a prior range of $645 to $675 million, net loss of $255 to $225 million versus a prior range of $245 to $225 million, adjusted net income (loss) of ($10) to $20 million versus a prior range of $10 to $30 million, and adjusted EBITDA of $110 to $140 million versus a prior range of $130 to $150 million1. Adjusted gross margin percentage guidance was revised upward, to 45% to 47% from a prior range of 42% to 44%1.
For the quarter, Emergent reported total revenues of $110.0 million, a net loss of $32.7 million with a net loss margin of (30)%, adjusted net loss of $18.7 million, gross margin of 14% and adjusted gross margin of 28%, and adjusted EBITDA loss of $4.6 million with an adjusted EBITDA margin of (4)%1, versus total revenues of $231.1 million and net income of $51.2 million in the same quarter of 20251.
At quarter end, the company's balance sheet showed cash and cash equivalents of $175.7 million, down from $205.4 million at December 31, 20251.
Fact check notes
- Checker's noteThe summary states the guidance revision 'narrows its full-year outlook,' but the filing shows most forecast ranges actually widened (e.g., revenue spread went from $30M to $45M, net loss spread from $20M to $30M, adjusted net income spread from $20M to $30M, adjusted EBITDA spread stayed at $30M vs $20M prior), making 'narrows' an inaccurate characterization—this was a downward (and in most cases wider-range) revision, not a narrowing.
- Sentence removed
On leadership, Emergent disclosed that Rich Lindahl, Executive Vice President and Chief Financial Officer, will retire effective December 31, 2026, and will stay on as a part-time advisor through March 31, 2027, with Frank Vargo, Vice President, Treasurer, serving as interim Chief Financial Officer beginning January 1, 2027.
copied source wording - Sentence removed
The company also said it completed repurchase of $75 million aggregate principal amount of Senior Unsecured Notes and implemented restructuring efforts aimed to improve overall cost structure, drive efficiencies and align resourcing to the current needs of the organization, including creation of a new Growth organization.
copied source wording
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.